Navigation Links
Nile Therapeutics, Inc. to Present at Upcoming BIO Investor Forum
Date:10/2/2007

BERKELEY, Calif., Oct. 2 /PRNewswire-FirstCall/ -- Nile Therapeutics, Inc. (OTC Bulletin Board: SPDU.OB), announced today that Peter M. Strumph, Chief Executive Officer, will present at the Biotechnology Industry Organization (BIO) Investor Forum on Thursday, October 11, 2007 at 12:30 p.m. Pacific Time at The Palace Hotel in San Francisco, California. Mr. Strumph will provide an overview of Nile and an update on its clinical development programs, including data from Nile's recently completed Phase Ia study for its lead compound, CD-NP.

The presentation will be webcast live and can be accessed by visiting the Investor Relations section at http://www.nilethera.com. The webcast will be archived for ninety days. Additional information regarding the BIO Investor Forum can be accessed at http://investorforum.bio.org.

About Nile Therapeutics, Inc.

Nile Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is developing innovative products for the treatment of cardiovascular disease. Nile is initially focusing its efforts on developing its lead compound, CD-NP, a novel chimeric peptide in Phase I studies for the treatment of heart failure and 2NTX-99, a small molecule, pre-clinical, anti-atherothrombotic agent with nitric oxide (NO) donating properties.

CD-NP, a novel chimeric natriuretic peptide currently in Phase I clinical studies for the treatment of heart failure, is a selective NPRB agonist which, in vivo, has been shown to have potent renal enhancement and cardiac unloading properties but with minimal hypotensive effects compared with competitive products. CD-NP is a rationally-designed synthetic peptide designed to incorporate favorable properties of naturally occurring natriuretic peptides. Data from Nile's recently completed Phase Ia study in healthy volunteers confirmed several pre-clinical findings, includin
'/>"/>

SOURCE Nile Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Canadian firm buys Proventiv Therapeutics, makes ex-Bone Care exec CEO
2. Amplification of genome-representative DNA from limited sources with GenomePlex WGA technology for use in genetic alterations studies
3. Wisconsin firms to present at Cleantech venture capital event
4. New Sonic Foundry search engine finds words, phrases in video presentations
5. Lone Wisconsin firm to present at InvestMidwest
6. Sonic Foundry creates search engine for 7,000 expert video presentations
7. InvestMidWest calls for business presentations
8. Wicab to present BrainPort at Boston conference
9. Three more Wisconsin firms to present at venture forum
10. Six Wisconsin firms to present at BIO Mid-America VentureForum
11. New Health and Human Services representative for Midwest
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... ... September 02, 2015 , ... Drug companies ... compounds. BCC Research reveals in its new report that the U.S. will ... the category and generates the most market demand. , BCC Research examines ...
(Date:9/2/2015)... 2, 2015 Aytu BioScience, Inc. (OTCQB: AYTU), ... urological and related conditions, announced today that it has ... convertible note financing, raising a total of $5.175 million, ... million. Josh Disbrow , Chief ... placement are intended to be used to conduct clinical ...
(Date:9/2/2015)... Israel , September 2, 2015 ... announced the intent of the National Institute of Allergy and ... Health (NIH) within the Department of Health and Human Services ... held in the United States in ... BiondVax,s universal flu vaccine candidate, Multimeric-001 (M-001), as a primer ...
(Date:9/2/2015)... ... September 02, 2015 , ... Whitehouse Laboratories is ... attending Pharma Ed Resources upcoming educational seminar and training session on Extractable & ... timely conference will provide Updates & Case Studies on the Latest Compliance Implications ...
Breaking Biology Technology:Plant-derived Compounds Poised to Assume Greater Role in Global Drug Markets, According to BCC Research 2Plant-derived Compounds Poised to Assume Greater Role in Global Drug Markets, According to BCC Research 3Aytu BioScience Completes $5.175 Million Private Placement 2Aytu BioScience Completes $5.175 Million Private Placement 3BiondVax Announces Intent to Launch a Phase 2 Trial in the United States in Collaboration with the U.S. National Institutes of Health 2BiondVax Announces Intent to Launch a Phase 2 Trial in the United States in Collaboration with the U.S. National Institutes of Health 3Whitehouse Laboratories to Participate in Pharm Ed Resources Extractables, Leachables, & Elemental Impurities Educational Seminar 2Whitehouse Laboratories to Participate in Pharm Ed Resources Extractables, Leachables, & Elemental Impurities Educational Seminar 3
... May 1 /PRNewswire-Asia/ -- Yongye Biotechnology International, Inc. (OTC ... distributor of plant and animal nutrient products located in ... of the independently owned Yongye branded retail stores in ... day sales.A Yongye branded retail store in Qianjiang City ...
... SAN DIEGO, May 1 BioMed Realty Trust, Inc. ... has entered into a new 15-year lease with Regeneron ... Landmark at Eastview campus in Tarrytown, New York, which ... lease expansion, Alan D. Gold, BioMed,s Chairman and Chief ...
... Held on May 15, 2009 at 8:00 am (Eastern) ... May 1 /PRNewswire-Asia/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: ... medical device R&D outsourcing company with operations in China ... release financial results for the first quarter of 2009 ...
Cached Biology Technology:Yongye Biotechnology Distributor has Record Breaking Single Store Sales Day 2Yongye Biotechnology Distributor has Record Breaking Single Store Sales Day 3BioMed Realty Trust Expands Landmark Leases With Regeneron Pharmaceuticals 2BioMed Realty Trust Expands Landmark Leases With Regeneron Pharmaceuticals 3WuXi PharmaTech Schedules First-Quarter 2009 Earnings Release 2
(Date:8/17/2015)... Aug. 17, 2015  NXT-ID, Inc. (NASDAQ: NXTD ... focused on the growing mobile commerce market and creator ... campaign for Q4 2015. The new marketing campaign is ... of Amplitude Marketing Group ( http://amplitudemarketing.com/ ) and TPMG ... a leader in retail driven marketing and brand awareness ...
(Date:8/11/2015)... GOTHENBURG, Sweden , August 11, 2015 ... sensor FPC1155. Already received as well as expected revenues in 2015 ... included in FPC,s communicated revenue guidance of approximately 2,200 MSEK for ... is a prominent smartphone manufacturer ... ZUK selected FPC1 155 ...
(Date:8/6/2015)... JOSE, Calif. , Aug. 6, 2015 /PRNewswire/ ... leading developer of human interface solutions, today announced ... TouchPad technologies on Windows 10. Microsoft leveraged Synaptics, ... to the operating system. Through ... drivers are fully certified with Microsoft,s Precision TouchPad ...
Breaking Biology News(10 mins):NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 2NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 3FPC's Touch Fingerprint Sensor FPC1155 in ZUK's Smartphone Z1 2Synaptics Chosen for Human Interface Co-Development on Windows 10 2
... Jr., M.D., one of the "fathers" of the ... receive the seventh annual American Association for Cancer ... Cancer Prevention Research. The award is given ... the field of cancer prevention research in basic, ...
... National Jewish Health have identified a simple gene-based blood ... patients, response to therapy than current tests. The test, ... care and help clear a backlog of promising medications ... published the results of a small "proof-of-principal" trial in ...
... Signal Patterns, SP Labs Election Patterns Report explains ... of voters; report also,reveals that openness and conscientiousness ... findings, PLEASANTVILLE, N.Y., Oct. 23 SP ... of scientific-based social web,applications that characterize and connect ...
Cached Biology News:Meyskens honored with AACR-Prevent Cancer Foundation award 2New test promises quicker, more accurate evaluation for cystic fibrosis patients 2New test promises quicker, more accurate evaluation for cystic fibrosis patients 3New Study Reveals the Emotional Impact and Effectiveness of Negative Campaigning 2New Study Reveals the Emotional Impact and Effectiveness of Negative Campaigning 3New Study Reveals the Emotional Impact and Effectiveness of Negative Campaigning 4
... and Non-ionic Detergent Removal , ... selective, virtually no cross-reactivity with other proteins ... pellet , Economical new surface technology, ... can often interfere with protein analysis. SurfactAway ...
... imaging system allows scanning of ... large as 40 x 46cm ... 25 microns. This system is ... in the proteomics field and ...
General description: MaxiSorp TM surface is ideal for arraying molecules with mixed hydrophilic/hydrophobic domains such as proteins ID clarifier: Maxisorp(tm) with lid...
... The Staccato Series of systems ... for today's drug discovery, genomics, proteomics ... are available in three base configurations; ... Custom Systems Series. All Staccato ...
Biology Products: